profit from every $100 of sales.
$0$100
Addex Therapeutics
$2.86+2.37% today
-66.5% in 1 year
1-year low $2.651-year high $8.99
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Addex Therapeutics sold, what it kept, and what it did with the cash.
Sales went from CHF 1.42 million in 2022 to CHF 29,972 in 2025, with -CHF 6.73 million of profit last year.
SalesProfit
Addex Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Addex Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Addex Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of CHF | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1 | 2 | 0 | 0 | |
| – | – | – | – | |
| -11 | -2 | -3 | -3 | |
| -10 | -2 | -5 | -7 | |
| -21 | -11 | 7 | -7 | |
| -55.20 | -16.80 | 8.40 | -7.20 | |
| – | – | – | – | |
| -741.0% | -139.1% | -681.8% | -9,390.8% | |
| -1,462.6% | -654.5% | 1,746.0% | -22,448.4% |
Balance sheet
| In millions of CHF | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 8 | 5 | 11 | 6 |
| Cash | 7 | 4 | 3 | 2 |
| Total debt | 0 | 0 | 0 | 0 |
| Total liabilities | 3 | 3 | 1 | 2 |
| 5 | 1 | 10 | 5 | |
| 1 | 1 | 1 | 1 | |
| -161.0% | -132.4% | -39.9% | -112.5% | |
| -423.5% | -921.6% | 72.9% | -141.2% |
Cash flow
| In millions of CHF | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -16 | -8 | -5 | -2 | |
| 0 | 0 | 0 | – | |
| -16 | -8 | -5 | -2 | |
| Dividends paid | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | |
| 4 | – | – | – |
Valuation
- –
- –
- –
- 1.4×
- 139.0×
- –
- –
- -52.1%
- -161.5%
- 0.0%
Profitability
- -4.8%
- -9,390.8%
- -22,448.4%
- -3,695.3%
- -54.5%
- -2.6%
- -102.6%
- -105.8%
- -54.5%
- 121.8%
Growth
- −72.4%
- –
- +32.8%
- –
- +34.7%
Financial health
- -0.2×
- 0.01
- 0.5%
- -175.9×
- 1.40
- 1.40
- 0.02
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 5%of 958
Bottom 1%of 889
Bottom 1%of 987
What analysts expect
- Average price target
- $30.00
- Range
- $30.00 – $30.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 30, 2026 | -1.94 | -1.42 | −36.0% |
| Dec 4, 2025 | -1.50 | – | – |
| Jun 20, 2025 | -1.33 | -4.26 | +68.8% |
| Apr 7, 2025 | -1.63 | -1.42 | −14.7% |
| Nov 22, 2024 | -2.77 | -1.40 | −97.9% |
| Sep 30, 2024 | -1.77 | -0.01 | −17,600.0% |
| Jun 6, 2024 | -1.37 | -0.44 | −210.3% |
| Apr 18, 2024 | -4.06 | -0.66 | −513.0% |
News
Addex Therapeutics reports 1H resultsSeeking Alpha · Sep 28, 2026The newest story we have is from Sep 28, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/6Passes 0 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
27No pass
Benjamin Graham
52No pass
Philip Fisher
33No pass
Peter Lynch
–Not enough data
Joel Greenblatt
0No pass
Charlie Munger
31No pass
Terry Smith
28No pass
Questions about Addex Therapeutics
Is Addex Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Addex Therapeutics AI analysis
What does Addex Therapeutics do?
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. It is in Biotechnology.
Does Addex Therapeutics pay a dividend?
No. Addex Therapeutics does not pay a dividend at the moment; in 2025 it returned $28,850 to shareholders by buying back its own shares.
Is Addex Therapeutics stock halal?
No. Addex Therapeutics does not pass our halal screen: its cash and confirmed interest-bearing investments are 39% of its market value, at or above the 33% limit. How we check
How has Addex Therapeutics stock done over the past year?
Down 66.5% over the past twelve months, to $2.86. It traded between $2.65 and $8.99 and is 68.2% below its high.
Who are Addex Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Addex Therapeutics's.
Prices: daily closes to Nov 10, 2026. Fundamentals: company reports via invest-like data.